Direct AMPK Activation Confers Mutation‐Independent Therapeutic Benefit in Duchenne Muscular Dystrophy
Journal of Cachexia, Sarcopenia and Muscle · 2026-02 · 17 (1)
DOI: 10.1002/jcsm.70200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 04.02.2026. Verfasst von Sean Y Ng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Kinesiology, McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, AMP-Activated Protein Kinases, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canada Research Chairs, Ontario Ministry of Economic Development, Job Creation and Trade.
Abstract (Originalsprache)
Background
Duchenne muscular dystrophy (DMD) is a severe, life‐limiting neuromuscular disorder (NMD) characterized by progressive muscle wasting and mitochondrial dysfunction. Although gene therapies offer promise, even those already approved by regulatory agencies, their use remains constrained by mutation specificity, delivery challenges and durability. Pharmacologically targeting AMPK has shown potential to ameliorate dystrophic pathology, but prior strategies have been hindered by inadequate efficacy and off‐target effects.
Methods
Comparative transcriptomic analyses were conducted to assess concordance between gene expression profiles induced by direct AMPK activation and those observed in DMD patient muscle. To evaluate the therapeutic potential of sustained AMPK activation, DBA/2J‐mdx (D2.mdx; n = 8–10) mice were treated daily with MK‐8722 (MK; 5 mg·kg −1 ) or vehicle for 7 weeks, with healthy DBA/2J mice serving as controls. Additionally, DMD patient‐derived myotubes ( n = 4) were treated with MK (1 μM, 24 h) to assess AMPK‐mediated cellular adaptations in human cells.
Results
Transcriptomic profiling revealed that MK modulated 206 DMD‐associated transcripts, reversing expression of 73 upregulated and 133 downregulated genes. In vivo, MK‐treated D2.mdx mice showed enhanced AMPK signalling (ACC phosphorylation, +120%–150%; p < 0.05), increased Ppargc1a expression (+60%, p < 0.05) and reduced inflammation‐ and fibrosis‐associated transcripts (−25%–50%; p < 0.05). Seven weeks of daily MK treatment enhanced (+95%; p < 0.05) whole‐body lipid oxidation during active periods without affecting energy expenditure or activity. Notably, we observed that repeated MK dosing did not adversely impact cardiac morphology or function ( p > 0.05). MK‐treated D2.mdx mice demonstrated improved grip strength fatigability (−35%, p < 0.05), inverted hang performance (+100%, p < 0.05) and treadmill exercise capacity (+20%, p < 0.05). Additional ex vivo muscle assessments revealed (+30%; p < 0.05) greater peak isometric force and improved twitch contractile kinetics. These functional adaptations were coincident with reduced myofibre damage and fibrosis, with increased sarcolemmal expression of utrophin, γ‐sarcoglycan and β‐dystroglycan (+10%–70%; p < 0.05), despite no changes in fibre size or mass. Mitochondrial assessments showed increased State III respiration (+80%; p < 0.05), reduced reactive oxygen species production (−70%; p < 0.05) and elevated OXPHOS protein content (+25%–45%; p < 0.05). In patient‐derived myotubes, MK similarly activated AMPK signalling, increased mitochondrial electron transport chain proteins (+25%–35%; p < 0.05) and enhanced maximal oxygen consumption (+50%–80%; p < 0.05) in DMDΔ44 and DMDΔ45 lines.
Conclusions
These findings demonstrate that sustained, systemic activation of AMPK safely improves muscle function, metabolic health and dystrophic pathology in a mutation‐independent manner. This supports the therapeutic potential of direct AMPK agonists as a disease‐modifying strategy for DMD and other neuromuscular disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Kinesiology, McMaster University, Hamilton, Ontario, Canada.
- Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
- Centre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, Ontario, Canada.
- Department of Kinesiology, Brock University, St. Catharines, Ontario, Canada.
- Department of Pediatrics, McMaster University Medical Centre, Hamilton, Ontario, Canada.
- Department of Medicine, Division of Endocrinology and Metabolism, McMaster University, Hamilton, Ontario, Canada.
ORCID-Profile: Vladimir Ljubicic
Förderung
- CIHR
- Canada Research Chairs
- Ontario Ministry of Economic Development, Job Creation and Trade
- Natural Sciences and Engineering Research Council of Canada Scholarships
- Ontario Graduate Scholarship
- Canadian Institutes of Health Research
Zitieren
APA
Ng, S. Y., Mikhail, A. I., Mattina, S. R., Lesinski, M. A., Rebalka, I. A., Hamstra, S. I., Xhuti, D., Fajardo, V. A., Tarnopolsky, M. A., Nederveen, J. P., Steinberg, G. R., Hawke, T. J., & Ljubicic, V. (2026). Direct AMPK Activation Confers Mutation‐Independent Therapeutic Benefit in Duchenne Muscular Dystrophy. Journal of Cachexia, Sarcopenia and Muscle, 17(1). https://doi.org/10.1002/jcsm.70200
Vancouver
Ng SY, Mikhail AI, Mattina SR, Lesinski MA, Rebalka IA, Hamstra SI, et al. Direct AMPK Activation Confers Mutation‐Independent Therapeutic Benefit in Duchenne Muscular Dystrophy. Journal of Cachexia, Sarcopenia and Muscle. 2026;17(1). doi:10.1002/jcsm.70200
BibTeX
@article{Ng2026,
author = {Ng, Sean Y and Mikhail, Andrew I and Mattina, Stephanie R and Lesinski, Magda A and Rebalka, Irena A and Hamstra, Sophie I and Xhuti, Donald and Fajardo, Val A and Tarnopolsky, Mark A and Nederveen, Joshua P and Steinberg, Gregory R and Hawke, Thomas J and Ljubicic, Vladimir},
title = {Direct AMPK Activation Confers Mutation‐Independent Therapeutic Benefit in Duchenne Muscular Dystrophy},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2026},
volume = {17},
number = {1},
doi = {10.1002/jcsm.70200}
}
EUVIMED